{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T03:24:30Z","timestamp":1786937070531,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Most chemotherapy regimens for poor-risk non-seminomatous germ cell tumours (PRGCT) deliver a fixed number of cycles; the role of variable treatment duration aiming for maximal response is unknown. Since the 1970s, we have utilised POMB\/ACE chemotherapy for PRGCT, treating until marker normalisation. From mid-1990s, treatment was limited to 7 cycles. We describe outcomes with POMB\/ACE for PRCGT, evaluating the association between treatment duration and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study across two UK tertiary cancer centres, identifying patients treated between 1978\u20132013. Complete response was defined based on normalisation of elevated tumour markers, absence of viable cancer in resection material and resolution of radiological abnormalities. Regression techniques were used to investigate the relationship between therapy duration and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      132 PRGCT patients completed POMB\/ACE with 69.7% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200992) alive at 5 years. Number of cycles delivered significantly correlated with recurrence free survival (HR 0.52; 95% CI 0.38\u20130.71;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and complete biochemical response (OR 1.27; 95% CI 1.10\u20131.49;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0018). POMB\/ACE discontinuation amongst patients with responding but not normalised tumour markers was associated with worse survival. Study limitations include the retrospective design.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>POMB\/ACE is highly active for PRGCT. Treatment until maximal biochemical response is associated with superior survival outcomes and warrants further exploration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03464-4","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:08:23Z","timestamp":1779926903000},"page":"708-716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Depth of response to primary POMB\/ACE chemotherapy predicts survival in poor prognosis germ-cell tumours"],"prefix":"10.1038","volume":"135","author":[{"given":"Emily","family":"Hobbs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Ulrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Sherpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Howlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hrouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethna","family":"Mannion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund H.","family":"Wilkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingky","family":"Lozano-Kuehne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eslam","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Rustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Tin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4078-2599","authenticated-orcid":false,"given":"Michael J.","family":"Seckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Ghorani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"3464_CR1","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.1997.15.2.594","volume":"15","author":"International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers","year":"1997","unstructured":"International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. Journal of Clinical Oncology. 1997;15:594\u2013603. https:\/\/doi.org\/10.1200\/JCO.1997.15.2.594.","journal-title":"Journal of Clinical Oncology"},{"key":"3464_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/bjc.1983.99","volume":"47","author":"MJ Peckham","year":"1983","unstructured":"Peckham MJ, Barrett A, Liew KH, Horwich A, Robinson B, Dobbs HJ, et al. The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP). Br J Cancer. 1983;47:613\u20139. https:\/\/doi.org\/10.1038\/bjc.1983.99.","journal-title":"Br J Cancer"},{"key":"3464_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1200\/JCO.2003.05.155","volume":"21","author":"JA Christian","year":"2003","unstructured":"Christian JA, Huddart RA, Norman A, Mason M, Fossa S, Aass N, et al. Intensive Induction Chemotherapy With CBOP\/BEP in Patients With Poor Prognosis Germ Cell Tumors. Journal of Clinical Oncology. 2003;21:871\u20137. https:\/\/doi.org\/10.1200\/JCO.2003.05.155.","journal-title":"Journal of Clinical Oncology"},{"key":"3464_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2019.12.028","volume":"127","author":"FH Cafferty","year":"2020","unstructured":"Cafferty FH, White JD, Shamash J, Hennig I, Stenning SP, Huddart RA. Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin\/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604). Eur J Cancer. 2020;127:139\u201349. https:\/\/doi.org\/10.1016\/j.ejca.2019.12.028.","journal-title":"Eur J Cancer"},{"key":"3464_CR5","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/S1470-2045(14)70490-5","volume":"15","author":"K Fizazi","year":"2014","unstructured":"Fizazi K, Pagliaro L, Laplanche A, Fl\u00e9chon A, Mardiak J, Geoffrois L, et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol. 2014;15:1442\u201350. https:\/\/doi.org\/10.1016\/S1470-2045(14)70490-5.","journal-title":"Lancet Oncol"},{"key":"3464_CR6","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1093\/annonc\/mdq575","volume":"22","author":"G Daugaard","year":"2011","unstructured":"Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Annals of Oncology. 2011;22:1054\u201361. https:\/\/doi.org\/10.1093\/annonc\/mdq575.","journal-title":"Annals of Oncology"},{"key":"3464_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JCO.2005.05.4528","volume":"25","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, et al. Phase III Randomized Trial of Conventional-Dose Chemotherapy With or Without High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Rescue As First-Line Treatment for Patients With Poor-Prognosis Metastatic Germ Cell Tumors. Journal of Clinical Oncology. 2007;25:247\u201356. https:\/\/doi.org\/10.1200\/JCO.2005.05.4528.","journal-title":"Journal of Clinical Oncology"},{"key":"3464_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/bju.14947","volume":"125","author":"J Shamash","year":"2020","unstructured":"Shamash J, Mee M, Sarker S, Wilson P, Ansell W, Greenwood M, et al. Dose-dense chemotherapy for untreated poor-prognosis and relapsed germ-cell tumours: an 18-year experience with GAMEC chemotherapy. BJU Int. 2020;125:843\u201352. https:\/\/doi.org\/10.1111\/bju.14947.","journal-title":"BJU Int"},{"key":"3464_CR9","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1200\/JCO.2016.34.15_suppl.4504","volume":"34","author":"K Fizazi","year":"2016","unstructured":"Fizazi K, Flechon A, Le Teuff G, Mardiak J, Pagliaro LC, Geoffrois L, et al. Mature results of the GETUG 13 phase III trial in poor-prognosis germ-cell tumors (GCT). Journal of Clinical Oncology. 2016;34:4504\u20134504. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.4504.","journal-title":"Journal of Clinical Oncology"},{"key":"3464_CR10","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1200\/JCO.23.01960","volume":"42","author":"K Fizazi","year":"2024","unstructured":"Fizazi K, Le Teuff G, Fl\u00e9chon A, Pagliaro L, Mardiak J, Geoffrois L, et al. Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. Journal of Clinical Oncology. 2024;42:3270\u20136. https:\/\/doi.org\/10.1200\/JCO.23.01960.","journal-title":"Journal of Clinical Oncology"},{"key":"3464_CR11","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S0140-6736(83)92079-2","volume":"321","author":"ES Newlands","year":"1983","unstructured":"Newlands ES, Rustin GJS, Begent RHJ, Parker D, Bagshawe KD. Further advances in the management of malignant teratomas of the testis and other sites. The Lancet. 1983;321:948\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(83)92079-2.","journal-title":"The Lancet"},{"key":"3464_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/bjc.1989.48","volume":"59","author":"R Hitchins","year":"1989","unstructured":"Hitchins R, Newlands E, Smith D, Begent R, Rustin G, Bagshawe K. Long-term outcome in patients with germ cell tumours treated with POMB\/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis. Br J Cancer. 1989;59:236\u201342. https:\/\/doi.org\/10.1038\/bjc.1989.48.","journal-title":"Br J Cancer"},{"key":"3464_CR13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1023\/A:1008279222625","volume":"8","author":"M Bower","year":"1997","unstructured":"Bower M, Newlands ES, Holden L, Rustin GJS, Begent RHJ. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB\/ACE chemotherapy. Annals of Oncology. 1997;8:477\u201383. https:\/\/doi.org\/10.1023\/A:1008279222625.","journal-title":"Annals of Oncology"},{"key":"3464_CR14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/0959-8049(95)00598-6","volume":"32","author":"M Bower","year":"1996","unstructured":"Bower M, Fife K, Holden L, Parardinas FJ, Rustin G, Newlands ES. Chemotherapy for ovarian germ cell tumours. Eur J Cancer. 1996;32:593\u20137.","journal-title":"Eur J Cancer"},{"key":"3464_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5968-7","volume":"19","author":"C Chan Wah Hak","year":"2019","unstructured":"Chan Wah Hak C, Coyle C, Kocache A, Short D, Sarwar N, Seckl MJ, et al. Emergency Etoposide-Cisplatin (Em-EP) for patients with germ cell tumours (GCT) and trophoblastic neoplasia (TN). BMC Cancer. 2019;19:770. https:\/\/doi.org\/10.1186\/s12885-019-5968-7.","journal-title":"BMC Cancer"},{"key":"3464_CR16","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/sj.bjc.6601664","volume":"90","author":"IA McNeish","year":"2004","unstructured":"McNeish IA, Kanfer EJ, Haynes R, Giles C, Harland SJ, Driver D, et al. Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours. Br J Cancer. 2004;90:1169\u201375. https:\/\/doi.org\/10.1038\/sj.bjc.6601664.","journal-title":"Br J Cancer"},{"key":"3464_CR17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/annonc\/mdw045","volume":"27","author":"N Adra","year":"2016","unstructured":"Adra N, Althouse SK, Liu H, Brames MJ, Hanna NH, Einhorn LH, et al. Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014. Annals of Oncology. 2016;27:875\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdw045.","journal-title":"Annals of Oncology"},{"key":"3464_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1200\/JCO.2007.13.8461","volume":"26","author":"S Culine","year":"2008","unstructured":"Culine S, Kramar A, Th\u00e9odore C, Geoffrois L, Chevreau C, Biron P, et al. Randomized Trial Comparing Bleomycin\/Etoposide\/Cisplatin With Alternating Cisplatin\/Cyclophosphamide\/Doxorubicin and Vinblastine\/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. Journal of Clinical Oncology. 2008;26:421\u20137. https:\/\/doi.org\/10.1200\/JCO.2007.13.8461.","journal-title":"Journal of Clinical Oncology"},{"key":"3464_CR19","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1359-6349(09)71433-8","volume":"7","author":"M Di Nicola","year":"2009","unstructured":"Di Nicola M, Necchi A, Nicolai N, Bengala C, Siena S, Novarino A, et al. 7100 High-dose sequential chemotherapy versus conventional-dose chemotherapy as first-line treatment for advanced poor prognosis germ-cell tumors: a multicenter Phase III Italian trial. European Journal of Cancer Supplements. 2009;7:422.","journal-title":"European Journal of Cancer Supplements"},{"key":"3464_CR20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1200\/JCO.2015.62.7000","volume":"34","author":"DR Feldman","year":"2016","unstructured":"Feldman DR, Lorch A, Kramar A, Albany C, Einhorn LH, Giannatempo P, et al. Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options\u2014An Analysis From the Global Germ Cell Cancer Group. Journal of Clinical Oncology. 2016;34:345\u201351. https:\/\/doi.org\/10.1200\/JCO.2015.62.7000.","journal-title":"Journal of Clinical Oncology"},{"key":"3464_CR21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejca.2017.09.029","volume":"87","author":"Y Loriot","year":"2017","unstructured":"Loriot Y, Pagliaro L, Fl\u00e9chon A, Mardiak J, Geoffrois L, Kerbrat P, et al. Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases. Eur J Cancer. 2017;87:140\u20136. https:\/\/doi.org\/10.1016\/j.ejca.2017.09.029.","journal-title":"Eur J Cancer"},{"key":"3464_CR22","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/cncr.28629","volume":"120","author":"A Hardt","year":"2014","unstructured":"Hardt A, Krell J, Wilson PD, Harding V, Chowdhury S, Mazhar D, et al. Brain metastases associated with germ cell tumors may be treated with chemotherapy alone. Cancer. 2014;120:1639\u201346. https:\/\/doi.org\/10.1002\/cncr.28629.","journal-title":"Cancer"},{"key":"3464_CR23","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/0277-5379(88)90081-8","volume":"24","author":"DB Smith","year":"1988","unstructured":"Smith DB, Rustin GJS, Hitchins R, Bagshawe KD, Hoskins P. Single agent activity of methotrexate in advanced non-seminomatous testicular germ cell tumours. Eur J Cancer Clin Oncol. 1988;24:1779\u201381. https:\/\/doi.org\/10.1016\/0277-5379(88)90081-8.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"3464_CR24","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1002\/cncr.32114","volume":"125","author":"D Morgensztern","year":"2019","unstructured":"Morgensztern D, Ko A, O\u2019Brien M, Ong TJ, Waqar SN, Socinski MA, et al. Association between depth of response and survival in patients with advanced-stage non\u2013small cell lung cancer treated with first-line chemotherapy. Cancer. 2019;125:2394\u20139. https:\/\/doi.org\/10.1002\/cncr.32114.","journal-title":"Cancer"},{"key":"3464_CR25","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"key":"3464_CR26","doi-asserted-by":"publisher","first-page":"22537","DOI":"10.18632\/oncotarget.25162","volume":"9","author":"S Zsch\u00e4bitz","year":"2018","unstructured":"Zsch\u00e4bitz S, Distler FA, Krieger B, Wuchter P, Sch\u00e4fer-Eckart K, Jenzer M, et al. Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease. Oncotarget. 2018;9:22537\u201345. https:\/\/doi.org\/10.18632\/oncotarget.25162.","journal-title":"Oncotarget"},{"key":"3464_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJMoa067749","volume":"357","author":"LH Einhorn","year":"2007","unstructured":"Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors. New England Journal of Medicine. 2007;357:340\u20138. https:\/\/doi.org\/10.1056\/NEJMoa067749.","journal-title":"New England Journal of Medicine"},{"key":"3464_CR28","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1200\/JCO.2009.25.1561","volume":"28","author":"DR Feldman","year":"2010","unstructured":"Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010;28:1706\u201313. https:\/\/doi.org\/10.1200\/JCO.2009.25.1561.","journal-title":"J Clin Oncol"},{"key":"3464_CR29","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nature20596","volume":"540","author":"A Taylor-Weiner","year":"2016","unstructured":"Taylor-Weiner A, Zack T, O\u2019Donnell E, Guerriero JL, Bernard B, Reddy A, et al. Genomic evolution and chemoresistance in germ-cell tumours. Nature. 2016;540:114\u20138. https:\/\/doi.org\/10.1038\/nature20596.","journal-title":"Nature"},{"key":"3464_CR30","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1200\/JCO.2001.19.9.2534","volume":"19","author":"M Mazumdar","year":"2001","unstructured":"Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ, Bosl GJ. Predicting Outcome to Chemotherapy in Patients With Germ Cell Tumors: The Value of the Rate of Decline of Human Chorionic Gonadotrophin and Alpha-Fetoprotein During Therapy. Journal of Clinical Oncology. 2001;19:2534\u201341. https:\/\/doi.org\/10.1200\/JCO.2001.19.9.2534.","journal-title":"Journal of Clinical Oncology"},{"key":"3464_CR31","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/sj.bmt.1700713","volume":"19","author":"C Weaver","year":"1997","unstructured":"Weaver C, Schwartzberg L, Hainsworth J, Greco F, Li W, Buckner C, et al. Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant. 1997;19:671\u20138. https:\/\/doi.org\/10.1038\/sj.bmt.1700713.","journal-title":"Bone Marrow Transplant"},{"key":"3464_CR32","doi-asserted-by":"publisher","first-page":"730","DOI":"10.4103\/ijmr.IJMR_1593_18","volume":"149","author":"L Kumar","year":"2019","unstructured":"Kumar L, Ramavath D, Kataria B, Tiwari A, Raj A, Chellapuram SK, et al. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma. Indian Journal of Medical Research. 2019;149:730\u20139. https:\/\/doi.org\/10.4103\/ijmr.IJMR_1593_18.","journal-title":"Indian Journal of Medical Research"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03464-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03464-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03464-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:44:19Z","timestamp":1786934659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03464-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9,5]]}},"alternative-id":["3464"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03464-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with institutional guidelines and regulations. This work was carried out as a National Health Service evaluation project and did not require external ethics review or consent from participants.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}